Davey, R. A. & Grossmann, M. Androgen receptor structure, function and biology: from bench to bedside.Clin. Biochem. Rev. 37, 3–15 (2016).
Karantanos, T., Corn, P. G. & Thompson, T. C. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 32, 5501–5511 (2013).
Cai, C. et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 20, 457–471 (2011).
Augello, M. A., Den, R. B. & Knudsen, K. E. AR function in promoting metastatic prostate cancer. Cancer Metastasis Rev. 33, 399–411 (2014).
Perlmutter, M. A. & Lepor, H. Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev. Urol. 9, S3–S8 (2007).
Kahn, B., Collazo, J. & Kyprianou, N. Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer. Int. J. Biol. Sci. 10, 588–595 (2014).
Rice, M. A., Malhotra, S. V. & Stoyanova, T. Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer. Front. Oncol. 9, 801 (2019).
Beer, T. M. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371, 424–433 (2014).
de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995–2005 (2011).
Ryan, C. J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138–148 (2013).
Fizazi, K. et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 20, 686–700 (2019).
Chi, K. N. et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncol. 19, 194–206 (2018).
Parker, C. C. et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392, 2353–2366 (2018).
Davis, I. D. et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N. Engl. J. Med. 381, 121–131 (2019).
Ku, S. Y., Gleave, M. E. & Beltran, H. Towards precision oncology in advanced prostate cancer. Nat. Rev. Urol. 16, 645–654 (2019).
Watson, P. A., Arora, V. K. & Sawyers, C. L. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat. Rev. Cancer 15, 701–711 (2015).
Beltran, H. et al. Aggressive variants of castration-resistant prostate cancer. Clin. Cancer Res. 20, 2846–2850 (2014).
Chaudhuri, O., Cooper-White, J., Janmey, P. A., Mooney, D. J. & Shenoy, V. B. Effects of extracellular matrix viscoelasticity on cellular behaviour. Nature 584, 535–546 (2020).
Liotta, L. A. & Kohn, E. C. The microenvironment of the tumour-host interface. Nature 411, 375–379 (2001).
Barnes, J. M. et al. A tension-mediated glycocalyx-integrin feedback loop promotes mesenchymal-like glioblastoma. Nat. Cell Biol. 20, 1203–1214 (2018).
Cherfils-Vicini, J. et al. Cancer cells induce immune escape via glycocalyx changes controlled by the telomeric protein TRF2. EMBO J. 38, https://doi.org/10.15252/embj.2018100012 (2019).
Paszek, M. J. et al. The cancer glycocalyx mechanically primes integrin-mediated growth and survival. Nature 511, 319–325 (2014).
Shurer, C. R. et al. Physical principles of membrane shape regulation by the glycocalyx. Cell 177, 1757–1770 e1721 (2019).
Woods, E. C. et al. A bulky glycocalyx fosters metastasis formation by promoting G1 cell cycle progression. Elife 6, https://doi.org/10.7554/eLife.25752 (2017).
Afar, D. E. et al. Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer. Mol. Cancer Ther. 3, 921–932 (2004).
Agerbaek, M. O. et al. The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent manner. Nat. Commun. 9, 3279 (2018).
Clausen, T. M. et al. Oncofetal chondroitin sulfate glycosaminoglycans are key players in integrin signaling and tumor cell motility. Mol. Cancer Res 14, 1288–1299 (2016).
De Klerk, D. P., Lee, D. V. & Human, H. J. Glycosaminoglycans of human prostatic cancer. J. Urol. 131, 1008–1012 (1984).
Edwards, I. J. Proteoglycans in prostate cancer. Nat. Rev. Urol. 9, 196–206 (2012).
Feferman, L. et al. Arylsulfatase B (N-acetylgalactosamine-4-sulfatase): potential role as a biomarker in prostate cancer. Prostate Cancer Prostatic Dis. 16, 277–284 (2013).
Feferman, L. et al. Arylsulfatase B is reduced in prostate cancer recurrences. Cancer Biomark. 21, 229–234 (2017).
Munkley, J. Glycosylation is a global target for androgen control in prostate cancer cells. Endocr. Relat. Cancer 24, R49–R64 (2017).
Munkley, J. et al. Androgen-regulated transcription of ESRP2 drives alternative splicing patterns in prostate cancer. Elife 8, https://doi.org/10.7554/eLife.47678 (2019).
Ricciardelli, C. et al. Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. Clin. Cancer Res. 4, 963–971 (1998).
Sakko, A. J. et al. Modulation of prostate cancer cell attachment to matrix by versican. Cancer Res. 63, 4786–4791 (2003).
Scott, E. & Munkley, J. Glycans as biomarkers in prostate cancer. Int. J. Mol. Sci. 20, https://doi.org/10.3390/ijms20061389 (2019).
Akamatsu, S. et al. The placental gene PEG10 promotes progression of neuroendocrine prostate cancer. Cell Rep. 12, 922–936 (2015).
Lin, D. et al. Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer. Oncotarget 6, 1806–1820 (2015).
Wyatt, A. W. et al. Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer. Genome Biol. 15, 426 (2014).
Thomas, M. A., Preece, D. M. & Bentel, J. M. Androgen regulation of the prostatic tumour suppressor NKX3.1 is mediated by its 3’ untranslated region. Biochem. J. 425, 575–583 (2010).
Clinckemalie, L. et al. Androgen regulation of the TMPRSS2 gene and the effect of a SNP in an androgen response element. Mol. Endocrinol. 27, 2028–2040 (2013).
Lucas, J. M. et al. The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma. J. Pathol. 215, 118–125 (2008).
Afar, D. E. et al. Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia. Cancer Res. 61, 1686–1692 (2001).
Magee, J. A., Chang, L. W., Stormo, G. D. & Milbrandt, J. Direct, androgen receptor-mediated regulation of the FKBP5 gene via a distal enhancer element. Endocrinology 147, 590–598 (2006).
Gery, S., Sawyers, C. L., Agus, D. B., Said, J. W. & Koeffler, H. P. TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells. Oncogene 21, 4739–4746 (2002).
Bluemn, E. G. et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell 32, 474–489 e476 (2017).
Vlachostergios, P. J., Puca, L. & Beltran, H. Emerging variants of castration-resistant prostate cancer. Curr. Oncol. Rep. 19, 32 (2017).
Mu, P. et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science 355, 84–88 (2017).
Handle, F. et al. Drivers of AR indifferent anti-androgen resistance in prostate cancer cells. Sci. Rep. 9, 13786 (2019).
Chen, Z. et al. Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer. EMBO J. 34, 502–516 (2015).
Chng, K. R. et al. A transcriptional repressor co-regulatory network governing androgen response in prostate cancers. EMBO J. 31, 2810–2823 (2012).
Salanti, A. et al. Targeting human cancer by a glycosaminoglycan binding malaria protein. Cancer Cell 28, 500–514 (2015).
Evers, M. R., Xia, G., Kang, H. G., Schachner, M. & Baenziger, J. U. Molecular cloning and characterization of a dermatan-specific N-acetylgalactosamine 4-O-sulfotransferase. J. Biol. Chem. 276, 36344–36353 (2001).
Mikami, T., Mizumoto, S., Kago, N., Kitagawa, H. & Sugahara, K. Specificities of three distinct human chondroitin/dermatan N-acetylgalactosamine 4-O-sulfotransferases demonstrated using partially desulfated dermatan sulfate as an acceptor: implication of differential roles in dermatan sulfate biosynthesis. J. Biol. Chem. 278, 36115–36127 (2003).
Smith, R. et al. Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease. Sci. Rep. 10, 21750 (2020).
Mahajan, R. Chondroitinase ABC enzyme: a potential treatment option for spinal cord injury. Int. J. Appl. Basic Med. Res. 8, 203 (2018).
Warren, P. M. et al. Secretion of a mammalian chondroitinase ABC aids glial integration at PNS/CNS boundaries. Sci. Rep. 10, 11262 (2020).
Lindahl, U., Couchman, J., Kimata, K. & Esko, J. D. Essentials of Glycobiology (eds Ajit Varki, Gerald W. Hart, Jeffrey D. Esko, Richard D. Cummings) 207–221 (2015).
Avram, S., Shaposhnikov, S., Buiu, C. & Mernea, M. Chondroitin sulfate proteoglycans: structure-function relationship with implication in neural development and brain disorders. Biomed. Res. Int. 2014, 642798 (2014).
Pudelko, A., Wisowski, G., Olczyk, K. & Kozma, E. M. The dual role of the glycosaminoglycan chondroitin-6-sulfate in the development, progression and metastasis of cancer. FEBS J. 286, 1815–1837 (2019).
Tarbell, J. M. & Cancel, L. M. The glycocalyx and its significance in human medicine. J. Intern. Med. 280, 97–113 (2016).
Hang, H. C., Yu, C., Kato, D. L. & Bertozzi, C. R. A metabolic labeling approach toward proteomic analysis of mucin-type O-linked glycosylation. Proc. Natl Acad. Sci. USA 100, 14846–14851 (2003).
Nigro, J. et al. Regulation of heparan sulfate and chondroitin sulfate glycosaminoglycan biosynthesis by 4-fluoro-glucosamine in murine airway smooth muscle cells. J. Biol. Chem. 284, 16832–16839 (2009).
Aparicio, A. M. et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin. Cancer Res. 19, 3621–3630 (2013).
Papandreou, C. N. et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J. Clin. Oncol. 20, 3072–3080 (2002).
Bishop, J. L. et al. The master neural transcription factor BRN2 is an androgen receptor-suppressed driver of neuroendocrine differentiation in prostate cancer. Cancer Discov. 7, 54–71 (2017).
Calcinotto, A. et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature 559, 363–369 (2018).
Karlou, M., Tzelepi, V. & Efstathiou, E. Therapeutic targeting of the prostate cancer microenvironment. Nat. Rev. Urol. 7, 494–509 (2010).
Orr, B. et al. Identification of stromally expressed molecules in the prostate by tag-profiling of cancer-associated fibroblasts, normal fibroblasts and fetal prostate. Oncogene 31, 1130–1142 (2012).
Tyekucheva, S. et al. Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer. Nat. Commun. 8, 420 (2017).
Valencia, T. et al. Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis. Cancer Cell 26, 121–135 (2014).
Wan, X. et al. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Sci. Transl. Med. 6, 252ra122 (2014).
Wu, J. B. et al. MAOA-dependent activation of Shh-IL6-RANKL signaling network promotes prostate cancer metastasis by engaging tumor-stromal cell interactions. Cancer Cell 31, 368–382 (2017).
Zhang, Z. et al. Tumor microenvironment-derived NRG1 promotes antiandrogen resistance in prostate cancer. Cancer Cell 38, 279–296.e279 (2020).
Seiler, R. et al. An oncofetal glycosaminoglycan modification provides therapeutic access to cisplatin-resistant bladder cancer. Eur. Urol. 72, 142–150 (2017).
Clausen, T. M. et al. A simple method for detecting oncofetal chondroitin sulfate glycosaminoglycans in bladder cancer urine. Cell Death Discov. 6, 65 (2020).
Mikami, T. & Kitagawa, H. Biosynthesis and function of chondroitin sulfate. Biochim. Biophys. Acta 1830, 4719–4733 (2013).
Oliveira-Ferrer, L., Hessling, A., Trillsch, F., Mahner, S. & Milde-Langosch, K. Prognostic impact of chondroitin-4-sulfotransferase CHST11 in ovarian cancer. Tumour Biol. 36, 9023–9030 (2015).
Chauchereau, A. et al. Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer. Exp. Cell Res. 317, 262–275 (2011).
Zhao, R. R. et al. Lentiviral vectors express chondroitinase ABC in cortical projections and promote sprouting of injured corticospinal axons. J. Neurosci. Methods 201, 228–238 (2011).
Klock, H. E. & Lesley, S. A. The Polymerase Incomplete Primer Extension (PIPE) method applied to high-throughput cloning and site-directed mutagenesis. Methods Mol. Biol. 498, 91–103 (2009).
Al Nakouzi, N. et al. Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis. EMBO Mol. Med. 8, 761–778 (2016).
Hong, V., Steinmetz, N. F., Manchester, M. & Finn, M. G. Labeling live cells by copper-catalyzed alkyne–azide click chemistry. Bioconjug Chem. 21, 1912–1916. https://doi.org/10.1021/bc100272z (2010).
Keough, M. B. et al. An inhibitor of chondroitin sulfate proteoglycan synthesis promotes central nervous system remyelination. Nat. Commun. 7, 11312 (2016).
Lawrence, R. et al. Evolutionary differences in glycosaminoglycan fine structure detected by quantitative glycan reductive isotope labeling. J. Biol. Chem. 283, 33674–33684 (2008).